Mega Genomics Limited (6667.HK)
HKD 7.71
(0.13%)
HKD 7.71
(0.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 163.68 Million | -6.91 Million | 30.62 Million | 102.83 Million | 37.27 Million |
| Net Income | 36.17 Million | -21.41 Million | 95.88 Million | 94.9 Million | 38.29 Million |
| Depreciation & Amortization | 15.12 Million | 15.27 Million | 13.87 Million | 14.03 Million | 14.05 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 7.28 Million | 4.94 Million | - | - | - |
| Change in working capital | 126.4 Million | -6.06 Million | -78.5 Million | -8.13 Million | -37.39 Million |
| Other non-cash items | -200 Thousand | 348 Thousand | -626 Thousand | 2.03 Million | 22.31 Million |
| Investing Cash Flow | -33.75 Million | -2.56 Million | -1.71 Million | -31.08 Million | 17.66 Million |
| Investments in PPE | -36.09 Million | -5.18 Million | -4.42 Million | -1.04 Million | -761 Thousand |
| Acquisitions | - | -2.44 Million | 263 Thousand | - | - |
| Investment purchases | -499.28 Million | -1.05 Billion | -546 Million | -30.04 Million | - |
| Sales/Maturities of investments | 501.62 Million | 1.05 Billion | 548.7 Million | - | - |
| Other Investing Activities | 2.1 Million | 2.44 Million | -263 Thousand | -30.04 Million | 18.42 Million |
| Financing Cash Flow | -12.91 Million | 158.45 Million | 2.62 Million | 84.05 Million | -20.27 Million |
| Debt repayment | -22.63 Million | -7.32 Million | -2.65 Million | -10.4 Million | -10.13 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -10.49 Million | - | -214.14 Million | - | - |
| Common Stock Issuance | - | 184.15 Million | 228.81 Million | - | - |
| Other Financing Activities | -15.5 Million | -18.37 Million | 204.73 Million | 94.46 Million | -10.14 Million |
| Accounts receivables | 82.92 Million | -7.04 Million | -79.56 Million | -21.38 Million | -20.25 Million |
| Accounts payables | - | 7.04 Million | 79.56 Million | 21.38 Million | 20.25 Million |
| Inventory | -901 Thousand | -224 Thousand | -312 Thousand | -532 Thousand | 536 Thousand |
| Other working capital | 39.59 Million | -5.84 Million | -78.18 Million | -7.6 Million | -37.92 Million |
| Cash at beginning of period | 399.83 Million | 239.09 Million | 208.45 Million | 52.64 Million | 17.98 Million |
| Cash at end of period | 518.28 Million | 399.83 Million | 239.09 Million | 208.45 Million | 52.64 Million |
| Capital Expenditure | -36.09 Million | -5.18 Million | -4.42 Million | -1.04 Million | -761 Thousand |
| Effect of forex changes on cash | 1.43 Million | 11.74 Million | -889 Thousand | - | - |
| Net cash flow / Change in cash | 118.45 Million | 160.73 Million | 30.64 Million | 155.8 Million | 34.66 Million |
| Free Cash Flow | 127.58 Million | -12.09 Million | 26.2 Million | 101.79 Million | 36.51 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 18.48 Million | 18.48 Million | -2.53 Million | 36.17 Million | -2.53 Million | 17.55 Million |
| Depreciation & Amortization | 3.59 Million | 3.59 Million | 3.76 Million | 15.12 Million | 3.72 Million | 3.75 Million |
| Deferred income taxes | - | - | - | - | - | -12.62 Million |
| Stock-based compensation | 606 Thousand | 606 Thousand | 1.82 Million | 7.28 Million | 1.82 Million | 1.81 Million |
| Change in working capital | -19.51 Million | -19.51 Million | 50.94 Million | 126.4 Million | 50.94 Million | 9.86 Million |
| Other non-cash items | 4.31 Million | 4.31 Million | -5.82 Million | -200 Thousand | -5.77 Million | 667 Thousand |
| Investing Cash Flow | 2.11 Million | 2.11 Million | -7.75 Million | -33.75 Million | -7.75 Million | -9.11 Million |
| Investments in PPE | -309.5 Thousand | -309.5 Thousand | -11.59 Million | -36.09 Million | -11.59 Million | -6.33 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -499.28 Million | - | - |
| Sales/Maturities of investments | - | - | - | 501.62 Million | - | - |
| Other Investing Activities | 2.42 Million | 2.42 Million | 3.83 Million | 2.1 Million | 3.83 Million | -2.78 Million |
| Financing Cash Flow | -14.22 Million | -14.22 Million | 3.34 Million | -12.91 Million | 3.34 Million | -9.8 Million |
| Debt repayment | - | - | - | -22.63 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -10.18 Million | -10.18 Million | -5.24 Million | -10.49 Million | -5.24 Million | -7.75 Million |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -4.03 Million | -4.03 Million | 8.59 Million | -15.5 Million | 8.59 Million | -2.05 Million |
| Accounts receivables | -15.91 Million | -15.91 Million | 30.78 Million | 82.92 Million | 30.78 Million | 10.67 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 1.6 Million | 1.6 Million | -581 Thousand | -901 Thousand | -581 Thousand | 130.5 Thousand |
| Other working capital | -5.2 Million | -5.2 Million | 20.73 Million | 39.59 Million | 20.73 Million | -939.5 Thousand |
| Cash at beginning of period | - | - | - | 399.83 Million | - | - |
| Cash at end of period | -4.67 Million | -4.67 Million | 43.81 Million | 518.28 Million | 43.81 Million | 15.41 Million |
| Capital Expenditure | -309.5 Thousand | -309.5 Thousand | -11.59 Million | -36.09 Million | -11.59 Million | -6.33 Million |
| Effect of forex changes on cash | -61 Thousand | -61 Thousand | 47.5 Thousand | 1.43 Million | 47.5 Thousand | 672 Thousand |
| Net cash flow / Change in cash | -4.67 Million | -4.67 Million | 43.81 Million | 118.45 Million | 43.81 Million | 15.41 Million |
| Free Cash Flow | 7.17 Million | 7.17 Million | 36.58 Million | 127.58 Million | 36.58 Million | 27.32 Million |
GELYY
600106
APGI
GGBR3
ILCO
CAE